A Pilot Study Comparing the Use of Low-target Versus Conventional Target Advagraf

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 24, 2011

Primary Completion Date

February 21, 2019

Study Completion Date

October 11, 2019

Conditions
Acute Graft RejectionDiabetes
Interventions
DRUG

Tacrolimus

"Low target tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1~Table 1~Months post tx:~0-1 month, level 5-7; 1-3 months, level 4-5; and 3-6 months, level 3-4"

DRUG

Tacrolimus

"Standard dose of tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1~Table 1~Months post tx~0-1 month; level 8-12; 1-3 months, level 6-9; and 3-6 months, level 5-8."

Trial Locations (1)

V6Z 1Y6

St. Paul's Hospital, Vancouver

All Listed Sponsors
collaborator

Astellas Pharma Canada, Inc.

INDUSTRY

lead

University of British Columbia

OTHER

NCT01265537 - A Pilot Study Comparing the Use of Low-target Versus Conventional Target Advagraf | Biotech Hunter | Biotech Hunter